Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | PRF1 | P14222 | 10/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15650233 | 0.89 | ALPL (0.44) | PIK3CBBRD4ALPLPRF1PIK3CA | |
| SCHEMBL22447323 | 0.89 | BRD4 (0.48) | PIK3CBBRD4ALPL | |
| SCHEMBL32670668 | 0.84 | BRD4 (0.50) | PIK3CBBRD4ALPLPRF1 | |
| SCHEMBL15648599 | 0.82 | BRD4 (0.47) | PIK3CBBRD4ALPL | |
| SCHEMBL790655 | 0.80 | PIK3C3 (0.53) | PIK3CA | |
| SCHEMBL31029634 | 0.79 | BRD4 (0.47) | PIK3CBBRD4ALPL | |
| SCHEMBL29556116 | 0.79 | PIK3CD (0.57) | PIK3CBBRD4ALPLPRF1PIK3CA | |
| SCHEMBL12276481 | 0.79 | PIK3CD (0.57) | PIK3CBBRD4ALPLPRF1PIK3CA | |
| SCHEMBL790984 | 0.79 | ALPL (0.48) | PIK3CBALPLPIK3CA | |
| SCHEMBL454986 | 0.79 | LMNA (0.49) | PRF1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105175411-B | The synthetic method of a kind of carbamide compounds and its salt compounds and application | 西安交通大学 | 2017-08-15 | — | — | CN | disclosed |
| US-9422298-B2 | Pyridopyrimidine derivatives and use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
| US-9422298-B2 | Pyridopyrimidine derivatives and use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
| US-9422298-B2 | Pyridopyrimidine derivatives and use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
| US-9388189-B2 | Pyrrolotriazinone derivatives as PI3K inhibitors | ALMIRALL, S.A. (ES) | 2016-07-12 | — | — | US | disclosed |
| US-20150291595-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2015-10-15 | — | — | US | disclosed |
| EP-2909207-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | Almirall S.A. (ES) | 2015-08-26 | — | — | EP | disclosed |
| US-20150158874-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CMG PHARMACEUTICAL CO., LTD. | 2015-06-11 | — | — | US | disclosed |
| US-20150158874-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CMG PHARMACEUTICAL CO., LTD. | 2015-06-11 | — | — | US | disclosed |
| US-20150158874-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CMG PHARMACEUTICAL CO., LTD. | 2015-06-11 | — | — | US | disclosed |
| US-8664230-B2 | Pyridopyrimidine derivatives and use thereof | THE ASAN FOUNDATION (KR) | 2014-03-04 | — | — | US | disclosed |
| US-8664230-B2 | Pyridopyrimidine derivatives and use thereof | THE ASAN FOUNDATION (KR) | 2014-03-04 | — | — | US | disclosed |
| US-20120238587-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238587-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238587-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-09-20 | — | — | US | disclosed |
| WO-2011121317-A9 | IMIDAZOTHIADIAZOLES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011121317-A1 | IMIDAZO [2,1-B] [1,3,4] THIADIAZOLES AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-10-06 | — | — | WO | disclosed |
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-2154965-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | Glaxosmithkline LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008150827-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | INPP5D, PI4KA, PTEN | PIK3CB 16/4885BRD4 3004/4885ALPL 1522/4885 |
| US-20150291595-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3CB, PIK3CD, PIK3CA | PIK3CB 1/4885BRD4 1873/4885ALPL 2893/4885 |
| US-20120238587-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | PIK3CA, PIK3CD, PI4KA | PIK3CB 6/4885BRD4 2209/4885ALPL 1664/4885 |
| US-20150158874-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | PIK3CA, PIK3CD, PI4KA | PIK3CB 6/4885BRD4 2209/4885ALPL 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.